Table 4.
Summary of prior reports on tCho quantification based on single-voxel acquisitions and comparison with the results reported in this paper
| First author/year | Field strength | Cases | Cancer prevalence (%) | Sensitivity (%) | Specificity (%) | tCho* range |
|---|---|---|---|---|---|---|
| Thakur/2011 [1] | 1.5 T | 88 | 64.8 | 96.5 | 93.5 | 0–47.1 |
| Baek/2012 [2] | 1.5 T | 112 | 88.4 | 65.7 | 92.3 | 0.9–10 |
| Sah/2012 [3] | 1.5 T | 189 | 79.9 | 76.2 | 76.3 | +0.58/1.6/4.2–5.4 |
| Suppiah/2012 [4] | 1.5 T | 57 | 73.7 | 95.2 | 93.3 | 0.1–6.9 |
| This study/2018 | 1.5 T | 103 | 71.8 | 95.9 | 48.3# | 0–16 |
* in mmol/l; +[1–4] no range given. Values indicate mean values for healthy tissue, benign and malignant lesions. Malignant lesions were reported in subgroups. #This study investigated only lesions classified as BI-RADS 4 or BI-RADS 5 after full triparametric (T2w, DWI, DCE) breast MRI assessment. Thus, the reported specificity does only apply to tCho quantification as investigated in this specific situation